Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $19
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $28 to $19.
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $28 to $19.